Literature DB >> 13973637

Clinical experience with methylglyoxal bis (guanylhydrazone) dihydrochloride: a new agent with clinical activity in acute myelocytic leukemia and the lymphomas.

W REGELSON, J R HOLLAND.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS; HYDRAZINES; LEUKEMIA, MYELOCYTIC; LYMPHOMA

Mesh：

Substances：

Year:  1963        PMID： 13973637

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  5 in total

1.  Phase II evaluation of MGBG in non-small cell carcinoma of the lung. A Southwest Oncology Group study.

Authors:  R B Vance; W A Knight; T T Chen; J J Costanzi; A F LoBuglio
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

2.  Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy.

Authors:  P J Creaven; R Perez; L Pendyala; N J Meropol; G Loewen; E Levine; E Berghorn; D Raghavan
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Treatment of patients with refractory myelogenous leukemia with BCOMM[1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)].

Authors:  T S Herman; B G Durie; J J Hutter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  Nonintercalative DNA-binding antitumour compounds.

Authors:  B C Baguley
Journal:  Mol Cell Biochem       Date:  1982-04-02       Impact factor: 3.396

Review 5.  PROGRESS IN CHEMOTHERAPY OF CANCER.

Authors:  W DAVIS; L F LARIONOV
Journal:  Bull World Health Organ       Date:  1964       Impact factor: 9.408
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.